| Abstract: | Patients with nonalcoholic fatty liver disease (NAFLD) often have hyperlipidemia and are at a higher risk of cardiovascular disease (CVD).1 As first-line lipid-lowering drugs, statins are widely used for primary and secondary CVD prevention.2 However, there have been concerns about statins underprescription for patients with NAFLD because of fear of hepatoxicity.3 We aimed to describe and compare the pattern of statins use before and after CVD events in patients with NAFLD with the general population. |
